BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Borovcanin MM, Janicijevic SM, Jovanovic IP, Gajovic N, Arsenijevic NN, Lukic ML. IL-33/ST2 Pathway and Galectin-3 as a New Analytes in Pathogenesis and Cardiometabolic Risk Evaluation in Psychosis. Front Psychiatry 2018;9:271. [PMID: 29988422 DOI: 10.3389/fpsyt.2018.00271] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Artık A, Kocaman O, Kara H, Tuncer SÇ. Galectin-3 levels in school aged children with autism spectrum disorder. International Journal of Developmental Disabilities 2022. [DOI: 10.1080/20473869.2022.2150035] [Reference Citation Analysis]
2 Minic Janicijevic S, Jovanovic IP, Gajovic NM, Jurisevic MM, Debnath M, Arsenijevic NN, Borovcanin MM. Galectin-3 mediated risk of inflammation in stable schizophrenia, with only possible secondary consequences for cognition. World J Psychiatry 2022; 12(9): 1183-1193 [DOI: 10.5498/wjp.v12.i9.1183] [Reference Citation Analysis]
3 Koricanac A, Tomic Lucic A, Veselinovic M, Bazic Sretenovic D, Bucic G, Azanjac A, Radmanovic O, Matovic M, Stanojevic M, Jurisic Skevin A, Simovic Markovic B, Pantic J, Arsenijevic N, Radosavljevic GD, Nikolic M, Zornic N, Nesic J, Muric N, Radmanovic B. Influence of antipsychotics on metabolic syndrome risk in patients with schizophrenia. Front Psychiatry 2022;13:925757. [DOI: 10.3389/fpsyt.2022.925757] [Reference Citation Analysis]
4 Mijailović NR, Vesic K, Arsenijevic D, Milojević-rakić M, Borovcanin MM. Galectin-3 Involvement in Cognitive Processes for New Therapeutic Considerations. Front Cell Neurosci 2022;16:923811. [DOI: 10.3389/fncel.2022.923811] [Reference Citation Analysis]
5 Ma H, Cheng N, Zhang C. Schizophrenia and Alarmins. Medicina (Kaunas) 2022;58:694. [PMID: 35743957 DOI: 10.3390/medicina58060694] [Reference Citation Analysis]
6 Dunleavy C, Elsworthy RJ, Upthegrove R, Wood SJ, Aldred S. Inflammation in first-episode psychosis: The contribution of inflammatory biomarkers to the emergence of negative symptoms, a systematic review and meta-analysis. Acta Psychiatr Scand 2022. [PMID: 35202480 DOI: 10.1111/acps.13416] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 11.0] [Reference Citation Analysis]
7 Borovcanin MM, Milovanovic M, Vesic K, Muric NN, Milovanovic J, Arsenijevic AN, Arsenijevic NN. Autoimmunity and psychosis. Translational Autoimmunity 2022. [DOI: 10.1016/b978-0-323-85415-3.00011-8] [Reference Citation Analysis]
8 Borovcanin MM, Vesic K. Breast cancer in schizophrenia could be interleukin-33-mediated. World J Psychiatr 2021; 11(11): 1065-1074 [PMID: 34888174 DOI: 10.5498/wjp.v11.i11.1065] [Reference Citation Analysis]
9 Borovcanin MM, Vesic K, Jovanovic M, Mijailovic NR. Galectin-3 possible involvement in antipsychotic-induced metabolic changes of schizophrenia: A minireview. World J Diabetes 2021; 12(10): 1731-1739 [PMID: 34754374 DOI: 10.4239/wjd.v12.i10.1731] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
10 Maruszewska-Cheruiyot M, Stear M, Donskow-Łysoniewska K. Galectins - Important players of the immune response to CNS parasitic infection. Brain Behav Immun Health 2021;13:100221. [PMID: 34589740 DOI: 10.1016/j.bbih.2021.100221] [Reference Citation Analysis]
11 Kozłowska E, Brzezińska-Błaszczyk E, Agier J, Wysokiński A, Żelechowska P. Alarmins (IL-33, sST2, HMGB1, and S100B) as potential biomarkers for schizophrenia. J Psychiatr Res 2021;138:380-7. [PMID: 33957300 DOI: 10.1016/j.jpsychires.2021.04.019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
12 Miao Y, Zhang ZX, Feng X, Sun WM. IL-33 as a Novel Serum Prognostic Marker of Intracerebral Hemorrhage. Oxid Med Cell Longev 2021;2021:5597790. [PMID: 33854693 DOI: 10.1155/2021/5597790] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
13 Pandolfo G, Genovese G, Casciaro M, Muscatello MRA, Bruno A, Pioggia G, Gangemi S. IL-33 in Mental Disorders. Medicina (Kaunas) 2021;57:315. [PMID: 33810498 DOI: 10.3390/medicina57040315] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
14 Srejovic IM, Lukic ML. Galectin-3 in T cell-mediated immunopathology and autoimmunity. Immunol Lett 2021;233:57-67. [PMID: 33753135 DOI: 10.1016/j.imlet.2021.03.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
15 Khavari B, Mahmoudi E, Geaghan MP, Cairns MJ. Oxidative Stress Impact on the Transcriptome of Differentiating Neuroblastoma Cells: Implication for Psychiatric Disorders. Int J Mol Sci 2020;21:E9182. [PMID: 33276438 DOI: 10.3390/ijms21239182] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Borovcanin MM, Minic Janicijevic S, Jovanovic IP, Gajovic NM, Jurisevic MM, Arsenijevic NN. Type 17 Immune Response Facilitates Progression of Inflammation and Correlates with Cognition in Stable Schizophrenia. Diagnostics (Basel) 2020;10:E926. [PMID: 33182582 DOI: 10.3390/diagnostics10110926] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
17 Srejovic I, Selakovic D, Jovicic N, Jakovljević V, Lukic ML, Rosic G. Galectin-3: Roles in Neurodevelopment, Neuroinflammation, and Behavior. Biomolecules 2020;10:E798. [PMID: 32455781 DOI: 10.3390/biom10050798] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 10.5] [Reference Citation Analysis]
18 Kiliç F, Işik Ü, Demirdaş A, Usta A. Serum galectin-3 levels are decreased in schizophrenia. Braz J Psychiatry 2020;42:398-402. [PMID: 32159713 DOI: 10.1590/1516-4446-2019-0699] [Reference Citation Analysis]
19 Isık Ü, Kılıç F, Demirdas A, Aktepe E, Aydogan Avsar P. Serum Galectin-3 Levels in Children with Attention-Deficit/Hyperactivity Disorder. Psychiatry Investig 2020;17:256-61. [PMID: 32151128 DOI: 10.30773/pi.2019.0247] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Momtazmanesh S, Zare-Shahabadi A, Rezaei N. Cytokine Alterations in Schizophrenia: An Updated Review. Front Psychiatry 2019;10:892. [PMID: 31908647 DOI: 10.3389/fpsyt.2019.00892] [Cited by in Crossref: 95] [Cited by in F6Publishing: 99] [Article Influence: 31.7] [Reference Citation Analysis]
21 Shao M, Tian H, Wang L, Jiang D, Ji F, Zhuo C. Mortality risk following acute coronary syndrome among patients with schizophrenia: A meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2020;96:109737. [PMID: 31442555 DOI: 10.1016/j.pnpbp.2019.109737] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]